• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心血管事件高危高血压患者的最佳血压目标

Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events.

作者信息

Aronow Wilbert S

机构信息

Department of Medicine, Division of Cardiology, New York Medical College, Valhalla, NY.

出版信息

Am J Ther. 2016 Jan-Feb;23(1):e218-23. doi: 10.1097/MJT.0b013e31827c5372.

DOI:10.1097/MJT.0b013e31827c5372
PMID:23591024
Abstract

Existing epidemiologic and clinical trial data suggest that the blood pressure in patients with hypertension at high risk for cardiovascular events because of coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or heart failure should be reduced to <140/90 mm Hg in patients younger than 80 years and the systolic blood pressure be reduced to 140-145 mm Hg if tolerated in patients aged 80 years and older. Studies from patients with coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, and heart failure will be discussed that support a blood pressure goal of <140/90 mm Hg in patients younger than 80 years at high risk for cardiovascular events.

摘要

现有流行病学和临床试验数据表明,因冠状动脉疾病、糖尿病、慢性肾病、中风或心力衰竭而具有心血管事件高风险的高血压患者,80岁以下患者的血压应降至<140/90 mmHg,80岁及以上患者若能耐受,收缩压应降至140 - 145 mmHg。将讨论来自冠状动脉疾病、糖尿病、慢性肾病、中风和心力衰竭患者的研究,这些研究支持心血管事件高风险的80岁以下患者的血压目标<140/90 mmHg。

相似文献

1
Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events.心血管事件高危高血压患者的最佳血压目标
Am J Ther. 2016 Jan-Feb;23(1):e218-23. doi: 10.1097/MJT.0b013e31827c5372.
2
What should the blood pressure goal be in patients with hypertension who are at high risk for cardiovascular disease?心血管疾病高危的高血压患者的血压目标应该是多少?
Hosp Pract (1995). 2012 Oct;40(4):28-32. doi: 10.3810/hp.2012.10.1000.
3
Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?收缩压低于150毫米汞柱对于老年人群心血管事件的一级预防而言是一个合适的目标吗?
J Am Soc Hypertens. 2014 Jul;8(7):491-7. doi: 10.1016/j.jash.2014.04.010. Epub 2014 May 5.
4
Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.2014 年高血压管理专家小组建议对当代心血管实践的影响:来自 NCDR PINNACLE 注册的见解。
J Am Coll Cardiol. 2014 Dec 2;64(21):2196-203. doi: 10.1016/j.jacc.2014.09.022. Epub 2014 Nov 19.
5
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).抗高血压和降脂治疗预防心脏病发作试验(ALLHAT):治疗抵抗性高血压与心血管疾病和终末期肾病的发病率。
Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.
6
Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view.支持60岁及以上患者收缩压目标低于150 mmHg的证据:少数观点。
Ann Intern Med. 2014 Apr 1;160(7):499-503. doi: 10.7326/M13-2981.
7
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).单片氨氯地平/阿托伐他汀有助于不同种族患者实现血压和血脂的推荐目标(双子座-AALA研究)。
J Hum Hypertens. 2009 Mar;23(3):196-210. doi: 10.1038/jhh.2008.114. Epub 2008 Sep 18.
8
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.钙拮抗剂与非钙拮抗剂治疗冠心病患者高血压的策略。国际维拉帕米-群多普利研究(INVEST):一项随机对照试验。
JAMA. 2003 Dec 3;290(21):2805-16. doi: 10.1001/jama.290.21.2805.
9
[Hypertension as a function of age].[高血压与年龄的关系]
Ital Heart J. 2000 Jun;1 Suppl 2:23-31.
10
How early should blood pressure control be achieved for optimal cardiovascular outcomes?血压控制应多早达标,才能获得最佳心血管结局?
J Hum Hypertens. 2011 Apr;25(4):211-7. doi: 10.1038/jhh.2010.64. Epub 2010 Jul 1.

引用本文的文献

1
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.严重高血压的发生显著改善转移性结直肠癌regorafenib 治疗的无进展生存期。
Int J Clin Oncol. 2023 Sep;28(9):1183-1190. doi: 10.1007/s10147-023-02364-4. Epub 2023 Jun 15.
2
Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.regorafenib 引起转移性结直肠癌治疗中重度高血压的风险因素分析。
Support Care Cancer. 2022 Dec;30(12):10203-10211. doi: 10.1007/s00520-022-07381-z. Epub 2022 Oct 11.
3
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
瑞戈非尼用于癌症患者时发生高血压的风险:一项系统评价和荟萃分析。
Eur J Clin Pharmacol. 2014 Feb;70(2):225-31. doi: 10.1007/s00228-013-1598-1. Epub 2013 Oct 23.